Intrinsic value of Alder BioPharmaceuticals - ALDR

Previous Close

$13.88

  Intrinsic Value

$1.03

stock screener

  Rating & Target

str. sell

-93%

Previous close

$13.88

 
Intrinsic value

$1.03

 
Up/down potential

-93%

 
Rating

str. sell

We calculate the intrinsic value of ALDR stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 0001), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 0.9

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
   2
   3
   4
   5
   6
   7
   8
   9
   10
   11
   12
   13
   14
   15
   16
   17
   18
   19
   20
   21
   22
   23
   24
   25
   26
   27
   28
   29
   30
   31

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  2.00
  2.30
  2.57
  2.81
  3.03
  3.23
  3.41
  3.57
  3.71
  3.84
  3.95
  4.06
  4.15
  4.24
  4.31
  4.38
  4.44
  4.50
  4.55
  4.59
  4.64
  4.67
  4.70
  4.73
  4.76
  4.78
  4.81
  4.83
  4.84
  4.86
Revenue, $m
  2
  2
  2
  2
  2
  2
  2
  2
  2
  2
  2
  2
  2
  3
  3
  3
  3
  3
  3
  3
  3
  4
  4
  4
  4
  4
  5
  5
  5
  5
Variable operating expenses, $m
  462
  472
  484
  498
  513
  530
  548
  567
  588
  611
  635
  661
  688
  717
  748
  781
  816
  852
  891
  932
  975
  1,021
  1,069
  1,120
  1,173
  1,229
  1,288
  1,350
  1,416
  1,484
Fixed operating expenses, $m
  132
  135
  138
  141
  144
  147
  150
  154
  157
  160
  164
  167
  171
  175
  179
  183
  187
  191
  195
  199
  204
  208
  213
  217
  222
  227
  232
  237
  242
  248
Total operating expenses, $m
  594
  607
  622
  639
  657
  677
  698
  721
  745
  771
  799
  828
  859
  892
  927
  964
  1,003
  1,043
  1,086
  1,131
  1,179
  1,229
  1,282
  1,337
  1,395
  1,456
  1,520
  1,587
  1,658
  1,732
Operating income, $m
  -592
  -605
  -620
  -637
  -655
  -675
  -696
  -719
  -743
  -769
  -797
  -826
  -857
  -890
  -924
  -961
  -1,000
  -1,040
  -1,083
  -1,128
  -1,176
  -1,225
  -1,278
  -1,333
  -1,391
  -1,452
  -1,516
  -1,583
  -1,653
  -1,727
EBITDA, $m
  -591
  -604
  -619
  -636
  -654
  -673
  -695
  -717
  -742
  -768
  -795
  -824
  -855
  -888
  -923
  -959
  -998
  -1,038
  -1,081
  -1,126
  -1,173
  -1,223
  -1,275
  -1,330
  -1,388
  -1,449
  -1,513
  -1,580
  -1,650
  -1,723
Interest expense (income), $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  2
  2
  2
  2
Earnings before tax, $m
  -592
  -605
  -620
  -637
  -655
  -675
  -696
  -719
  -743
  -769
  -797
  -826
  -857
  -890
  -925
  -961
  -1,000
  -1,041
  -1,084
  -1,129
  -1,176
  -1,226
  -1,279
  -1,334
  -1,392
  -1,453
  -1,517
  -1,584
  -1,655
  -1,729
Tax expense, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Net income, $m
  -592
  -605
  -620
  -637
  -655
  -675
  -696
  -719
  -743
  -769
  -797
  -826
  -857
  -890
  -925
  -961
  -1,000
  -1,041
  -1,084
  -1,129
  -1,176
  -1,226
  -1,279
  -1,334
  -1,392
  -1,453
  -1,517
  -1,584
  -1,655
  -1,729

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  33
  34
  35
  36
  37
  38
  39
  41
  42
  44
  45
  47
  49
  51
  54
  56
  58
  61
  64
  67
  70
  73
  76
  80
  84
  88
  92
  97
  101
  106
Adjusted assets (=assets-cash), $m
  33
  34
  35
  36
  37
  38
  39
  41
  42
  44
  45
  47
  49
  51
  54
  56
  58
  61
  64
  67
  70
  73
  76
  80
  84
  88
  92
  97
  101
  106
Revenue / Adjusted assets
  0.061
  0.059
  0.057
  0.056
  0.054
  0.053
  0.051
  0.049
  0.048
  0.045
  0.044
  0.043
  0.041
  0.059
  0.056
  0.054
  0.052
  0.049
  0.047
  0.045
  0.043
  0.055
  0.053
  0.050
  0.048
  0.045
  0.054
  0.052
  0.050
  0.047
Average production assets, $m
  5
  5
  6
  6
  6
  6
  6
  6
  7
  7
  7
  8
  8
  8
  9
  9
  9
  10
  10
  11
  11
  12
  12
  13
  13
  14
  15
  15
  16
  17
Working capital, $m
  -18
  -19
  -19
  -20
  -21
  -21
  -22
  -23
  -24
  -24
  -25
  -26
  -28
  -29
  -30
  -31
  -33
  -34
  -36
  -37
  -39
  -41
  -43
  -45
  -47
  -49
  -52
  -54
  -57
  -59
Total debt, $m
  -4
  -4
  -3
  -3
  -2
  -1
  -1
  0
  1
  2
  3
  4
  5
  7
  8
  9
  11
  12
  14
  16
  18
  19
  21
  24
  26
  28
  31
  33
  36
  39
Total liabilities, $m
  20
  20
  21
  21
  22
  22
  23
  24
  25
  26
  27
  28
  29
  30
  32
  33
  35
  36
  38
  40
  41
  43
  45
  48
  50
  52
  55
  57
  60
  63
Total equity, $m
  13
  14
  14
  15
  15
  15
  16
  17
  17
  18
  18
  19
  20
  21
  22
  23
  24
  25
  26
  27
  28
  30
  31
  33
  34
  36
  38
  39
  41
  43
Total liabilities and equity, $m
  33
  34
  35
  36
  37
  37
  39
  41
  42
  44
  45
  47
  49
  51
  54
  56
  59
  61
  64
  67
  69
  73
  76
  81
  84
  88
  93
  96
  101
  106
Debt-to-equity ratio
  -0.320
  -0.280
  -0.230
  -0.190
  -0.140
  -0.090
  -0.040
  0.010
  0.060
  0.120
  0.170
  0.220
  0.270
  0.310
  0.360
  0.410
  0.450
  0.500
  0.540
  0.580
  0.620
  0.650
  0.690
  0.730
  0.760
  0.790
  0.820
  0.850
  0.880
  0.910
Adjusted equity ratio
  0.407
  0.407
  0.407
  0.407
  0.407
  0.407
  0.407
  0.407
  0.407
  0.407
  0.407
  0.407
  0.407
  0.407
  0.407
  0.407
  0.407
  0.407
  0.407
  0.407
  0.407
  0.407
  0.407
  0.407
  0.407
  0.407
  0.407
  0.407
  0.407
  0.407

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  -592
  -605
  -620
  -637
  -655
  -675
  -696
  -719
  -743
  -769
  -797
  -826
  -857
  -890
  -925
  -961
  -1,000
  -1,041
  -1,084
  -1,129
  -1,176
  -1,226
  -1,279
  -1,334
  -1,392
  -1,453
  -1,517
  -1,584
  -1,655
  -1,729
Depreciation, amort., depletion, $m
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  2
  2
  2
  2
  2
  2
  2
  2
  2
  2
  2
  2
  3
  3
  3
  3
  3
  3
  3
Funds from operations, $m
  -591
  -604
  -619
  -636
  -654
  -673
  -695
  -717
  -742
  -768
  -795
  -824
  -855
  -888
  -923
  -960
  -998
  -1,039
  -1,082
  -1,127
  -1,174
  -1,224
  -1,277
  -1,332
  -1,390
  -1,450
  -1,514
  -1,581
  -1,652
  -1,725
Change in working capital, $m
  0
  0
  0
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -2
  -2
  -2
  -2
  -2
  -2
  -2
  -2
  -2
  -2
  -3
  -3
Cash from operations, $m
  -590
  -603
  -618
  -635
  -653
  -673
  -694
  -717
  -741
  -767
  -794
  -823
  -854
  -887
  -922
  -958
  -997
  -1,037
  -1,080
  -1,125
  -1,172
  -1,222
  -1,275
  -1,330
  -1,387
  -1,448
  -1,512
  -1,579
  -1,649
  -1,723
Maintenance CAPEX, $m
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -2
  -2
  -2
  -2
  -2
  -2
  -2
  -2
  -2
  -2
  -2
  -2
  -3
  -3
  -3
  -3
  -3
  -3
New CAPEX, $m
  1
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
Cash from investing activities, $m
  0
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -2
  -2
  -2
  -2
  -2
  -2
  -2
  -2
  -2
  -3
  -3
  -3
  -4
  -4
  -4
  -4
  -4
  -4
Free cash flow, $m
  -591
  -605
  -620
  -636
  -654
  -674
  -695
  -718
  -742
  -768
  -796
  -825
  -856
  -889
  -924
  -960
  -999
  -1,040
  -1,083
  -1,128
  -1,175
  -1,225
  -1,277
  -1,333
  -1,391
  -1,451
  -1,515
  -1,582
  -1,653
  -1,727
Issuance/(repayment) of debt, $m
  -4
  0
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  2
  2
  2
  2
  2
  2
  2
  2
  2
  3
  3
  3
  3
Issuance/(repurchase) of shares, $m
  -3
  605
  620
  637
  655
  675
  696
  719
  744
  770
  797
  827
  858
  891
  926
  962
  1,001
  1,042
  1,085
  1,130
  1,178
  1,228
  1,280
  1,336
  1,394
  1,455
  1,519
  1,586
  1,657
  1,731
Cash from financing (excl. dividends), $m  
  -7
  605
  621
  638
  656
  676
  697
  720
  745
  771
  798
  828
  859
  892
  927
  963
  1,002
  1,044
  1,087
  1,132
  1,180
  1,230
  1,282
  1,338
  1,396
  1,457
  1,522
  1,589
  1,660
  1,734
Total cash flow (excl. dividends), $m
  -598
  1
  1
  1
  2
  2
  2
  2
  2
  2
  2
  3
  3
  3
  3
  3
  4
  4
  4
  4
  4
  5
  5
  5
  5
  6
  6
  6
  7
  7
Retained Cash Flow (-), $m
  -589
  -605
  -620
  -637
  -655
  -675
  -696
  -719
  -744
  -770
  -797
  -827
  -858
  -891
  -926
  -962
  -1,001
  -1,042
  -1,085
  -1,130
  -1,178
  -1,228
  -1,280
  -1,336
  -1,394
  -1,455
  -1,519
  -1,586
  -1,657
  -1,731
Prev. year cash balance distribution, $m
  263
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
  -589
  -604
  -619
  -636
  -654
  -673
  -695
  -717
  -741
  -767
  -795
  -824
  -855
  -888
  -922
  -959
  -997
  -1,038
  -1,081
  -1,126
  -1,173
  -1,223
  -1,275
  -1,330
  -1,388
  -1,449
  -1,513
  -1,580
  -1,650
  -1,724
Discount rate, %
  4.30
  4.52
  4.74
  4.98
  5.23
  5.49
  5.76
  6.05
  6.35
  6.67
  7.00
  7.35
  7.72
  8.11
  8.51
  8.94
  9.39
  9.86
  10.35
  10.87
  11.41
  11.98
  12.58
  13.21
  13.87
  14.56
  15.29
  16.05
  16.86
  17.70
PV of cash for distribution, $m
  -565
  -553
  -539
  -523
  -507
  -489
  -469
  -448
  -426
  -402
  -377
  -352
  -325
  -298
  -271
  -244
  -217
  -191
  -166
  -143
  -121
  -101
  -84
  -68
  -54
  -42
  -32
  -24
  -18
  -13
Current shareholders' claim on cash, %
  100.0
  7.0
  0.5
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0

Alder BioPharmaceuticals, Inc., is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize genetically engineered therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. Alder's lead pivotal-stage product candidate, eptinezumab, is being evaluated for migraine prevention. Eptinezumab is a monoclonal antibody that inhibits calcitonin gene-related peptide (CGRP), a protein that is active in mediating the initiation of migraine. Alder is additionally evaluating ALD1910, a preclinical product candidate also in development as a migraine prevention therapy. ALD1910 is a monoclonal antibody that inhibits pituitary adenylate cyclase-activating polypeptide-38 (PACAP-38), another protein that is active in mediating the initiation of migraine. Clazakizumab, Alder's third program, is a monoclonal antibody candidate that inhibits interleukin-6 and is licensed to Vitaeris, Inc.

FINANCIAL RATIOS  of  Alder BioPharmaceuticals (ALDR)

Valuation Ratios
P/E Ratio -4.5
Price to Sales 0
Price to Book 1.8
Price to Tangible Book
Price to Cash Flow -4.4
Price to Free Cash Flow -4.2
Growth Rates
Sales Growth Rate -100%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate 600%
Cap. Spend. - 3 Yr. Gr. Rate NaN%
Financial Strength
Quick Ratio NaN
Current Ratio 0
LT Debt to Equity 0%
Total Debt to Equity 0%
Interest Coverage 0
Management Effectiveness
Return On Assets -38.6%
Ret/ On Assets - 3 Yr. Avg. -18.5%
Return On Total Capital -40.5%
Ret/ On T. Cap. - 3 Yr. Avg. -3.9%
Return On Equity -40.5%
Return On Equity - 3 Yr. Avg. -3.9%
Asset Turnover 0
Profitability Ratios
Gross Margin 0%
Gross Margin - 3 Yr. Avg. 0%
EBITDA Margin 0%
EBITDA Margin - 3 Yr. Avg. 6.1%
Operating Margin 0%
Oper. Margin - 3 Yr. Avg. 5.5%
Pre-Tax Margin 0%
Pre-Tax Margin - 3 Yr. Avg. 5.5%
Net Profit Margin 0%
Net Profit Margin - 3 Yr. Avg. 5.5%
Effective Tax Rate 0%
Eff/ Tax Rate - 3 Yr. Avg. 0%
Payout Ratio 0%

ALDR stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the ALDR stock intrinsic value calculation we used $1.619 million for the last fiscal year's total revenue generated by Alder BioPharmaceuticals. The default revenue input number comes from 0001 income statement of Alder BioPharmaceuticals. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our ALDR stock valuation model: a) initial revenue growth rate of 2% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 4.3%, whose default value for ALDR is calculated based on our internal credit rating of Alder BioPharmaceuticals, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of Alder BioPharmaceuticals.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of ALDR stock the variable cost ratio is equal to 27950%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $129 million in the base year in the intrinsic value calculation for ALDR stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 5.4% for Alder BioPharmaceuticals.

Corporate tax rate of 27% is the nominal tax rate for Alder BioPharmaceuticals. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the ALDR stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for ALDR are equal to 317.7%.

Life of production assets of 2.1 years is the average useful life of capital assets used in Alder BioPharmaceuticals operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for ALDR is equal to -1117.6%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $279.275 million for Alder BioPharmaceuticals - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 67.85 million for Alder BioPharmaceuticals is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of Alder BioPharmaceuticals at the current share price and the inputted number of shares is $0.9 billion.

RELATED COMPANIES Price Int.Val. Rating
PFE Pfizer 44.28 34.10  hold
REGN Regeneron Phar 356.66 335.37  hold
LLY Eli Lilly 112.21 67.15  sell
JNJ Johnson&Johnso 145.34 176.79  buy
AMGN Amgen 193.16 130.16  sell
ABEO Abeona Therape 9.36 0.83  str.sell

COMPANY NEWS

▶ Alder BioPharmaceuticals: 3Q Earnings Snapshot   [Nov-05-18 06:20PM  Associated Press]
▶ Alder BioPharmaceuticals: 2Q Earnings Snapshot   [Aug-07-18 06:36PM  Associated Press]
▶ Teva Scraps A Study In Cluster Headaches And This Rival Benefits   [Jun-15-18 05:01PM  Investor's Business Daily]
▶ Ex-Juno leader becomes CEO of Alder BioPharmaceuticals ahead of migraine drug launch   [Jun-11-18 06:01PM  American City Business Journals]
▶ Why Alder's CEO Hire Could Indicate It's Seeking A Buyer   [Jun-07-18 05:15PM  Investor's Business Daily]
▶ Alder BioPharmaceuticals: 1Q Earnings Snapshot   [May-08-18 05:24PM  Associated Press]
▶ Alder BioPharmaceuticals poaches Amgen vet for new chief operating officer role   [Apr-23-18 03:40PM  American City Business Journals]
▶ Alder BioPharmaceuticals posts 4Q loss   [05:00AM  Associated Press]
▶ Best High Growth AMEX Stocks This Week   [Jan-20-18 11:02AM  Simply Wall St.]
▶ Winners & losers from JP Morgan Healthcare Conference   [Jan-16-18 07:36PM  CNBC Videos]
▶ 3 Biotech Stocks That Soared This Week: Are They Buys?   [Jan-13-18 10:32AM  Motley Fool]
▶ Cramer Remix: This is the day to buy Facebook   [Jan-12-18 07:10PM  CNBC Videos]
▶ Alder Biopharmaceuticals Meets 80-Plus Relative Strength Rating Benchmark   [Jan-11-18 03:00AM  Investor's Business Daily]
▶ Why Alder Biopharma Is Winning Big on Monday   [Jan-08-18 10:50AM  24/7 Wall St.]

CONTACT US       ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2018. All rigths reserved.